Global antibody glycosylation is dynamic and plays critical roles in shaping different immunological outcomes and direct antibody functionality during HIV infection. However, the relevance of global antibody or plasma glycosylation patterns to HIV persistence after antiretroviral therapy (ART) has not been characterized. First, we compared glycomes of total plasma and isolated immunoglobulin G (IgG) from HIV+ ART-suppressed, HIV+ viremic, and HIV-negative individuals. Second, in ART-suppressed individuals, we examined the associations between glycomes and (1) levels of cell-associated HIV DNA and RNA in PBMCs and isolated CD4+ T cells, (2) CD4 count and CD4%, and (3) expression of CD4+ T-cell activation markers. HIV infection is associated with persistent alterations in the IgG glycome including decreased levels of disialylated glycans, which is associated with a lower anti-inflammatory activity, and increased levels of fucosylated glycans, which is associated with lower antibody-dependent cell-mediated cytotoxicity (ADCC). We also show that levels of certain mono-and digalactosylated nonfucosylated glycomic traits (A2G1, A2G2, and A2BG2), which have been reported to be associated with higher ADCC and higher antiinflammatory activities, exhibit significant negative correlations with levels of cell-associated total HIV DNA and HIV RNA in ART-suppressed individuals. Finally, levels of certain circulating antiinflammatory glycans are associated with higher levels of CD4 T cells and lower levels of T-cell activation. Our findings represent the first proof-of-concept evidence that glycomic alterations, known to be associated with differential states of inflammation and ADCC activities, are also associated with levels of HIV persistence in the setting of ART suppression.
involve multifactorial mechanisms including possible on-going HIV production, cytomegalovirus infection, loss of Tregs, microbial translocation, and other factors. [14] [15] [16] [17] [18] Identifying novel host determinants governing this cycle in vivo is an important step in developing effective strategies to cure HIV infection and/or prevent the development of inflammation-associated HIV comorbidities.
Recent advances in the glycobiology field show that host glycosylation and glycan-lectin signaling play critical roles in immune responses 19 and in cell-cell 20 and cell-pathogen interactions. 21 Altered glycosylation is documented in many diseases including cancer, [22] [23] [24] [25] autoimmune, 26, 27 and infectious diseases. 28, 29 Altered serum cell-free glycan structures have been identified as biomarkers for cancer [22] [23] [24] [25] and various cellular processes. 26, 27 Glycans can enter the circulation from tissues through active secretion or leakage, but antibody glycosylation also plays a critical role in the impact of circulating glycans on the immune system. 30 Glycosylation can alter the antibody capacity to interact with classical and nonclassical Fc receptors, which defines the antibody functionality in inducing antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and anti-inflammatory activities. [31] [32] [33] [34] Higher levels of antibody galactosylation and lower levels of fucosylation are associated with a higher ADCC function of antibodies. [35] [36] [37] Antibody sialylation and galactosylation are linked to strong anti-inflammatory responses [38] [39] [40] [41] ; however, the exact mechanism underlies this effect is not clear. It has been suggested that it could be related to either switching the antibody's binding from classic Fc receptors to nonclassical Fc receptors, 42, 43 or binding to sialic-acid-binding proteins (siglecs) on the surface of monocytes and macrophages, thus initiating an inhibitory signal that leads to an anti-inflammatory response through inhibition of TLR4 signal transduction. [44] [45] [46] [47] HIV infection has been associated with certain changes in antibody glycosylation, mainly higher levels of agalactosylated antibodies. 28, 48 Changes in global and antigen-specific antibody glycosylation have been associated with a differential activity of anti-HIV antibodies to control HIV infection. 28 However, as yet, there are no data linking antibody glycosylation to the HIV latent reservoir during suppressive ART. In this study, we hypothesized that the ability of antibody glycosylation to impact several immunological responses, including ADCC and immune activation/inflammation, would play a role in defining HIV reservoir size during ART. To address this hypothesis, we examined relationships between the glycomes of plasma and total immunoglobulin G (IgG) and nucleic-acid measures of HIV persistence during ART.
METHODS

Study population
Fresh PBMCs and plasma from HIV-infected ART-suppressed (viral load < 20 copies/ml), HIV-infected unsuppressed (viral load > 50 copies/ml), and HIV-negative individuals were included in the analysis (Supplemental Table 1 ) and obtained from Philadelphia FIGHT and The Wistar Institute. Written informed consent was provided by all patients and donors recruited, and the protocols used were approved by the Institutional Review Boards of the University of Pennsylvania and The Wistar Institute. Plasma RNA viral load, CD4+ T-cell counts, and CD4% were measured at all patient visits.
T-cell immunophenotyping
Markers of T-cell activation (HLA-DR, CD69, and CD25) that have been associated with HIV latency [49] [50] [51] [52] [53] were measured using flow cytometry. Briefly, freshly isolated PBMCs were stained with LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen) and then stained with the following fluorescently conjugated monoclonal antibodies: CD3 BV421 (clone UCHT1), CD4 PE-Cy7 (clone RPA-T4), CD25 BV605 (clone BC96), HLA-DR FITC (clone L243) from Biolegend. CD69 PE (clone FN50) from BD Biosciences. Stained cells were fixed in PBS with 1% paraformaldehyde, and stored in the dark at 4 • C until acquisition. All phenotyping data were collected on BD LSR II (BD Biosciences). Data were analyzed using FlowJo software (Treestar).
qPCR quantification of cellular HIV-1 DNA and RNA
CD4+ T cells were isolated from PBMCS using EasySep Human CD4+ T-cell enrichment kit (Stemcell Technologies, Vancouver, British Columbia, Canada). Cellular RNA and DNA from total unfractionated PBMCs and isolated CD4+ T cells were purified using the AllPrep DNA/RNA kit (Qiagen, Ventura CA) as specified by the manufacturer, quantified using a Nanodrop (ND-1000) spectrophotometer and full-length NL4-3 virion RNA followed by copy number determination using the Abbott Real Time assay (Abbott Diagnostics, Des Plains, Ill) and calibrated to VQA HIV-1 RNA standards. Patient specimens were assayed with up to 800 ng total cellular RNA or DNA in replicate reaction wells and copy number determined by extrapolation against a 7-point standard curve (1-10,000 cps) performed in triplicate. with PNGase F, labeled with 2-aminobenzamide and excess of regents removed by clean-up using hydrophilic interaction liquid chromatography solid phase extraction (HILIC-SPE), as previously described. 54, 55 Eluates were stored at -20 • C until the ultra-performance liquid chromatography (UPLC) analysis. Fluorescently labeled and purified N-glycans were separated by HILIC-UPLC using Acquity UPLC instrument (Waters, Milford, MA, USA) as previously described. 54, 55 IgG Nglycan samples were all separated into 24 peaks 30 and total plasma N-glycans into 39 peaks. 56 The amount of N-glycans in each chromatographic peak was expressed as a percentage of total integrated area (% Area). From these directly measured IgG and total plasma Nglycans, additional glycan traits have been derived to assess changes in the amount of glycan classes that represent structurally similar glycan species (Supplemental Tables 2 and 3 ).
IgG isolation from plasma
Statistical analyses
Data were analyzed using Prism 7.0 (GraphPad Software, La Jolla, CA, USA 
RESULTS
HIV infection is associated with persistent alterations in the IgG glycome
The glycomes of isolated IgG from HIV-negative controls, HIV+ ARTsuppressed individuals (viral load < 20 copies/ml), and HIV+ unsuppressed individuals (viral load = > 50 copies/ml) (Supplemental Table   1 ) were profiled using UPLC. IgG N-glycans were separated into 24 chromatographic peaks 30 (Supplemental Fig. 1A ). Each peak represents a glycan trait. Certain IgG glycan traits were combined into categories, glycan structures that contain galactose (G0 = agalactosylated, G1 = mono-galactosylated, G2 = digalactosylated) or that contain sialic acid (S = sialylated), fucose (F = fucosylated), or a bisecting GlcNAc (B = bisected) (Supplemental Table 2 ). Levels of disialy- In particular, decreased levels of IgG sialylated glycans, which is associated with proinflammatory activity, [38] [39] [40] and increased levels of IgG fucosylated glycans, which is associated with lower ADCC and higher inflammation, [35] [36] [37] 58, 59 regardless of the ART-suppression status.
Plasma glycomic alterations are associated with HIV infection
The glycomes of plasma ( Fig. 2 ) from the same individuals as above were profiled using UPLC. Total plasma N-glycans were Each peak represents a glycan trait. Additionally, structurally similar glycan species were combined into derived traits to assess changes in the levels of galactosylation, sialylation, fucosylation, bisecting GlcNAc, and branching ( Fig. 2A , Supplemental Table 3 
Levels of glycomic traits in isolated IgG and total plasma glycomes correlate with nucleic acid measures of HIV persistence during ART
To test the hypothesis that glycomic alterations in plasma or IgG can affect HIV reservoir size during suppressive ART, we examined relationships between nucleic acid measures of the latent reservoir and both the glycomes of isolated IgG and total plasma. Levels of cell-associated HIV total DNA and HIV RNA were measured in unfractionated PBMCs and negatively selected peripheral blood CD4+ T cells from HIV+ ART-suppressed individuals within the above-mentioned cohort. Levels of total HIV DNA and cell-associated HIV RNA in both unfractionated PBMC and isolated CD4+ were negatively correlated with levels of three glycan traits in isolated IgG (Fig. 3 ) and three glycan traits in total plasma (Fig. 4 ). All these glycan structures are similar in that they are mono-or digalactosylated, with (Fig. 3C) .
Levels of A2 [6] BG1 (monogalactosylated structure with bisecting GlcNAc, with no sialic acid or core fucose) in total plasma glycome inversely correlated with levels of total HIV DNA in unfractionated PBMC (P = 0.018, rho = -0.63) and isolated CD4+ T cells (P = 0.002, rho = -0.758), and inversely correlated with levels of cell-associated HIV RNA in isolated CD4+ T cells (P = 0.009, rho = -0.68) (Fig. 4A) .
Levels of A2G2 (digalatosylated glycan structure, with no sialic acid or core fucose) in total plasma glycome inversely correlated with levels of total HIV DNA in unfractionated PBMC (P = 0.05, rho = -0.53) and isolated CD4+ T cells (P = 0.0077, rho = -0.69), and inversely correlated with levels of cell-associated HIV RNA in unfractionated PBMC (P = 0.048, rho = -0.54) and isolated CD4+ T cells (P = 0.04, rho = -0.56) (Fig. 4B) . Levels of A2BG2 (digalactosylated glycan structure with bisecting GlcNAc, with no sialic acid or core fucose) in total plasma glycome inversely correlated with levels of total HIV DNA in unfractionated PBMC (P = 0.019, rho = -0.63) and isolated CD4+ T cells (P = 0.0018, rho = -0.77), and inversely correlated with levels of cellassociated HIV RNA in unfractionated PBMC (P = 0.02, rho = -0.6) and isolated CD4+ T cells (P = 0.007, rho = -0.7) (Fig. 4C) .
Interestingly, the levels of A2G2 were higher in the IgG glycomes of HIV+ ART-suppressed individuals (median = 1%, IQR = 0.9) when compared to HIV-negative controls (P = 0.01, median = 0.6%, IQR = 0.3), (Fig. 5) . To test if age played a role in the observed relationships, we examined the correlations between the expression of these glycan traits and age. No correlation was detected between age and levels of A2G1, A2G2, A2BG2 in isolated IgG glycome or age and levels of A2 [6] BG1, A2G2, and A2BG2 in total plasma glycome (Supplemental Fig. 2 ). In addition, all significant glycan associations with HIV DNA/RNA loads were tested using linear regression with both glycan abundance and age as factors, and none of the results lost significance indicating independence of glycan association from age. (Figs. 6E and F) . Levels of FA2BG2S in IgG glycome positively correlated with CD4 count (P = 0.001, rho = 0.8) (Fig. 6G) . Levels of A2BG2 in total plasma inversely correlated with the percentage of CD4+ T cells expressing the CD69 early activation marker (P = 0.045, rho = -0.55) (Fig. 6H) . was confirmed in our study. 28, 48 In addition, we revealed that certain glycomic alterations that have been associated with inflammation (a loss of disialylated glycans and an increase of fucosylated glycans) and Our secondary objective was to assess the relationship between the plasma and IgG glycomes and cellular activation in the setting of ART.
Levels of circulating anti-inflammatory glycans associate with higher levels of CD4 count and lower levels of T-cell activation
Cell-based measurements of viral persistence are consistently associated with markers of immune activation. 65 In line with our hypothesis, levels of glycans known to promote anti-inflammatory activity S.K.V and I.T-A. contributed equally to this work.
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